|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
|
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash | ||||||||
| Prepaid expenses | ||||||||
| Short-term prepaid insurance | ||||||||
| Cash and cash equivalents | ||||||||
| Short-term investments | ||||||||
| Accounts receivable, net | ||||||||
| Prepaid expenses and other current assets | ||||||||
| Capitalized transaction costs (Note 2) | ||||||||
| Total current assets | ||||||||
| Deferred offering costs | ||||||||
| Long-term prepaid insurance | ||||||||
| Investments held in Trust Account | ||||||||
| Property and equipment, net | ||||||||
| Operating lease right-of-use assets, net | ||||||||
| Restricted cash | ||||||||
| Deposits | ||||||||
| Total assets | ||||||||
| LIABILITIES, MEZZANINE EQUITY, AND STOCKHOLDERS' DEFICIT | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | ||||||||
| Accrued expenses | ||||||||
| Promissory note - related party | ||||||||
| Accrued offering costs | ||||||||
| Cash underwriting fee payable | ||||||||
| Long-term debt, current portion, net ($19,175 at fair value and $96 at amortized cost, net as of December 31, 2025) (Note 8) | ||||||||
| Deferred revenue | ||||||||
| Contract loss provision | ||||||||
| Operating lease liabilities, current | ||||||||
| Long-term debt, current portion, net | ||||||||
| Convertible promissory notes (Note 8) | ||||||||
| Total current liabilities | ||||||||
| Deferred underwriting fee | ||||||||
| Deferred underwriting fee payable | ||||||||
| Deferred underwriting fee payable | ||||||||
| Operating lease liabilities, non-current | ||||||||
| Warrant liabilities (Note 9) | ||||||||
| Long-term debt, non-current portion, net ($12,207 at fair value and $577 at amortized cost, net as of December 31, 2025) (Note 8) | ||||||||
| Total liabilities | ||||||||
| Series A Preferred Stock and Redeemable convertible preferred stock | ||||||||
| Class A Ordinary Shares | ||||||||
| Series A Preferred Stock | ||||||||
| Redeemable convertible preferred stock | ||||||||
| Total series A Preferred Stock and Redeemable convertible preferred stock | ||||||||
| Stockholders' deficit: | ||||||||
| Common stock: $0.0001 par value; 800,000,000 and 138,655,675 shares authorized; 100,592,160 and 69,663,395 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | ||||||||
| Class A Ordinary Shares | ||||||||
| Class B Ordinary Shares | ||||||||
| Total common stock: $0.0001 par value; 800,000,000 and 138,655,675 shares authorized; 100,592,160 and 69,663,395 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | ||||||||
| Additional paid-in capital | ||||||||
| Accumulated deficit | ||||||||
| Total stockholders' deficit | ||||||||
| Total liabilities, mezzanine equity, and stockholders' deficit |
Loading...
